The Global Autoimmune Disease Diagnostics Market Is Witnessing High Growth Owing To the High Developments by Key Companies in the Market
Autoimmune Disease Diagnostics Market
Autoimmune
Disease Diagnostics Market - Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2022-2028.
Market Overview:
There
are many different types of medicines that are used for autoimmune
diseases. Some medications target specific parts of the immune system,
while others suppress the immune system in general. While many medications are
effective, some may cause side effects and can increase the risk of infection.
Some of the most common types of medications for autoimmune diseases are
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and
immunosuppressant medications. These drugs are used to suppress the immune
system and keep it from attacking healthy cells. NSAIDs are a popular drug to
use for inflammatory conditions, and they are generally quick to relieve
symptoms. Corticosteroids are used for autoimmune diseases because they have
strong anti-inflammatory properties. In some cases, a doctor can identify an
autoimmune disease by testing the patient's blood for antibodies.
Autoantibodies are proteins that the immune system makes to attack specific
organs or tissues. As a result of an autoimmune disease, a person's immune
system can't tell the difference between an invader and a normal part of their
body.
Competitive Landscape:
Major
players operating in the global
autoimmune disease diagnostics market include AESKU.GROUP GMBH & CO.
KG, KRONUS, ORGENTEC Diagnostika, A. Menarini Diagnostics s.r.l, Cambridge Life
Sciences Limited, Exagen Inc., Seramun Diagnostica GmbH, HTG Molecular
Diagnostics, Oncimmune, EUROIMMUN AG, HYCOR Biomedical, Werfen, Trinity
Biotech, Grifols, Bio-Rad Laboratories, Danaher, Abbott, Siemens, and Thermo
Fisher Scientific.
Key Market Drivers:
Increasing
developments in the global autoimmune disease diagnostics market are expected
to augment the growth of the market. For instance, in November 2019, Exagen
Inc. extended the agreement with GSK for the third time, in order to boost
great awareness related to restraints faced by lupus management and diagnosis.
Doctors and scientists are working to understand the mechanisms behind
autoimmune diseases. Although there is still much to learn about the immune
system, it has been proven that these disorders can be treated effectively.
Depending on the nature of the disease, a person with an autoimmune disorder
will typically experience flare-ups, as well as comorbidities. Moreover, the
high incidence of autoimmune diseases in the world is estimated to enhance the
growth of the global autoimmune disease diagnostics market.
Covid-19 Impact Analysis:
During
the COVID-19 pandemic, there have been several developments in the global
autoimmune disease diagnostics market. For instance, in August 2022, KSL
Beutner Laboratories (Beutner) introduced a blood test in order to diagnose the
antigen, which is related with the autoimmune blistering disease mucous
membrane pemphigoid (MMP) that results in painful lesions in the oral cavity.
Key Takeaways:
·
North America is
expected to dominate the growth of the global autoimmune disease diagnostics
market, owing to the increasing developments by key market players in the
region. For instance, in May 2022, Thermofisher's Phadia 2500+ series of
instruments was made available for testing autoimmune diseases in the United
States.
·
The Asia Pacific
is estimated to witness high growth in the global autoimmune disease
diagnostics market, owing to the high prevalence of biotechnology labs in the
region. For instance, according to the Australian Trade and Investment
Commission (Austrade), there are over 470 biotechnology companies in Australia.
Comments
Post a Comment